Academic Journal
Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study.
| Τίτλος: | Unveiling the association between plasma lipid species and pan-cancers: A bidirectional 2-sample Mendelian randomization study. |
|---|---|
| Συγγραφείς: | Cui X; Department of Anesthesiology, Jilin Provincial People's Hospital, Changchun, Jilin, China., Yang X; Department of Pathology, The First Hospital of Jilin University, Changchun, Jilin, China., Piao G; Department of Anesthesiology, Jilin Provincial People's Hospital, Changchun, Jilin, China. |
| Πηγή: | Medicine [Medicine (Baltimore)] 2026 Sep 25; Vol. 105 (39), pp. e50711. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins |
| Ιατρικοί όροι (MeSH): | Lipids*/blood , Neoplasms*/blood , Neoplasms*/genetics , Mendelian Randomization Analysis*, Humans ; Female ; Risk Factors |
| Περίληψη: | Plasma lipids play a crucial role at every stage of cancer progression, and a deficiency or excess of plasma lipids can lead to an increased risk of cancer. Previous observational studies and randomized controlled trials on the association between plasma lipids and cancer risk have been limited. We conducted a Mendelian randomization (MR) analysis to assess the impact of 179 plasma lipid species on the risk of 15 types of cancer. Through bidirectional 2-sample MR analysis and colocalization analysis, we systematically studied the association between 179 plasma lipid species and 15 types of cancer. In the MR study, we primarily used inverse variance weighting as our analytical strategy. Sensitivity analyses were carried out using the MR-Egger method and the MR Pleiotropy Residual Sum and Outlier method. We rigorously assessed heterogeneity through the application of Cochrane Q test. To ensure the robustness of the MR results, we employed the "leave-one-out" method and tested the strength of the causal relationships through false discovery rate correction. We identified a significant causal relationship between 20 plasma lipid species and the risk of 5 types of cancer. Specifically, in the forward MR analysis, the level of plasma phosphatidylethanolamine (18:0_20:4) was causally linked with pancreatic cancer; the level of plasma phosphatidylcholine (O-18:0_16:1) was causally linked with breast cancer (estrogen receptor [ER]+); the level of plasma phosphatidylcholine (O-16:0_20:3) was causally linked with endometrial cancer (endometrioid histology); 3 plasma lipid species were causally linked with lung cancer; and 14 plasma lipid species were causally linked with colorectal cancer. Strong evidence from colocalization analysis confirmed that 11 plasma lipid species shared causal variants with the risk of colorectal cancer. In the reverse analysis, an increased risk of colorectal cancer was associated with elevated levels of plasma phosphatidylcholine (18:1_18:2). This discovery held strong in comprehensive sensitivity analyses. We did not find a clear link between other plasma lipids and cancer. Our research results powerfully demonstrated the role of plasma lipids in cancer risk. (Copyright © 2026 the Author(s). Published by Wolters Kluwer Health, LLC.) |
| Competing Interests: | The authors have no funding and conflicts of interest to declare. |
| References: | Lancet Glob Health. 2016 Sep;4(9):e609-16. (PMID: 27470177) BMJ. 2018 Jul 12;362:k601. (PMID: 30002074) Diabetes Care. 2016 Dec;39(12):2232-2239. (PMID: 27703025) CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. (PMID: 26742998) Front Oncol. 2023 Jan 11;12:1110104. (PMID: 36713567) Genet Epidemiol. 2013 Nov;37(7):658-65. (PMID: 24114802) Nat Rev Mol Cell Biol. 2020 Apr;21(4):225-245. (PMID: 31848472) Nat Genet. 2017 May;49(5):680-691. (PMID: 28346442) Gut Microbes. 2024 Jan-Dec;16(1):2320291. (PMID: 38417029) Cancers (Basel). 2021 Jul 08;13(14):. (PMID: 34298629) Oncogene. 2022 Dec;41(49):5266-5278. (PMID: 36316442) Genome Biol. 2021 Jan 13;22(1):32. (PMID: 33441155) Lipids Health Dis. 2016 Apr 04;15:67. (PMID: 27044508) Sci Rep. 2021 Oct 13;11(1):20322. (PMID: 34645896) Eur J Nutr. 2021 Sep;60(6):3171-3184. (PMID: 33544207) Nat Commun. 2018 Jan 22;9(1):322. (PMID: 29358673) Front Med (Lausanne). 2023 Jul 31;10:1148542. (PMID: 37588002) BMJ Open. 2022 Jun 22;12(6):e052373. (PMID: 35732386) Nat Commun. 2018 Aug 9;9(1):3166. (PMID: 30093612) Eur J Hum Genet. 2019 Oct;27(10):1589-1598. (PMID: 31231134) J Steroid Biochem Mol Biol. 2023 Sep;232:106346. (PMID: 37321513) Nature. 2021 Nov;599(7886):628-634. (PMID: 34662886) PLoS Genet. 2014 May 15;10(5):e1004383. (PMID: 24830394) Int J Mol Sci. 2023 Jan 17;24(3):. (PMID: 36768152) Curr Opin Pharmacol. 2012 Dec;12(6):690-5. (PMID: 22884562) Front Oncol. 2023 Nov 03;13:1276654. (PMID: 38023258) Lipids Health Dis. 2007 Jul 10;6:17. (PMID: 17623088) Adv Sci (Weinh). 2022 Apr;9(12):e2105222. (PMID: 35170250) Nat Genet. 2021 Oct;53(10):1415-1424. (PMID: 34594039) J Proteome Res. 2021 Jan 1;20(1):740-750. (PMID: 33241689) Int J Cancer. 2019 Apr 15;144(8):1941-1953. (PMID: 30350310) Nat Commun. 2023 Oct 31;14(1):6934. (PMID: 37907536) Int J Cancer. 2020 Jun 15;146(12):3256-3266. (PMID: 31495913) Diabetes Care. 2020 Feb;43(2):366-373. (PMID: 31818810) World J Gastroenterol. 2014 Jul 14;20(26):8646-52. (PMID: 25024621) Stat Med. 2016 May 20;35(11):1880-906. (PMID: 26661904) JCI Insight. 2022 Feb 8;7(3):. (PMID: 34914638) Int J Mol Sci. 2023 Sep 11;24(18):. (PMID: 37762264) Biol Psychiatry. 1998 Oct 15;44(8):775-7. (PMID: 9798082) Nat Genet. 2014 Jul;46(7):736-41. (PMID: 24880342) Free Radic Biol Med. 2019 Nov 20;144:293-309. (PMID: 31152791) Int J Mol Sci. 2022 May 09;23(9):. (PMID: 35563655) Nat Genet. 2018 Jul;50(7):928-936. (PMID: 29892016) CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593) Gut. 2010 Nov;59(11):1572-85. (PMID: 20660702) J Clin Oncol. 2007 Jul 1;25(19):2696-701. (PMID: 17602074) Nat Genet. 2016 Dec;48(12):1544-1550. (PMID: 27749845) Biomolecules. 2021 Mar 11;11(3):. (PMID: 33799830) Front Immunol. 2022 Feb 15;13:768606. (PMID: 35250970) |
| Contributed Indexing: | Keywords: Mendelian randomization; cancers; genetic causal association; plasma lipids |
| Substance Nomenclature: | 0 (Lipids) |
| Entry Date(s): | Date Created: 20260926 Date Completed: 20260926 Latest Revision: 20260930 |
| Update Code: | 20260930 |
| PubMed Central ID: | PMC13619218 |
| DOI: | 10.1097/MD.0000000000050711 |
| PMID: | 42798079 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1536-5964 |
|---|---|
| DOI: | 10.1097/MD.0000000000050711 |